Universität zu Köln

Mor, Joel M. and Heindl, Ludwig M. (2017). Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma. Ocul. Oncol. Pathol., 3 (2). S. 133 - 142. BASEL: KARGER. ISSN 2296-4657

Full text not available from this repository.

Abstract

Aim: In this review, we outline similarities between conjunctival and skin melanoma as well as the effectiveness of combined BRAF/MEK inhibition in melanoma, and discuss the applicability of these agents in conjunctival melanoma. Methods: The study provides a PubMed literature review. Results: Conjunctival melanoma and skin melanoma are genetically and phenotypically related. Both tumors typically harbor BRAF mutations in more than 50% of cases. New targeted therapies in metastatic skin melanoma include selective inhibition of BRAF and MEK. Combined BRAF/MEK inhibition has revolutionized the treatment of metastatic skin melanoma, significantly improving patients' prognoses. While these new substances have been investigated extensively in the treatment of skin melanoma, comparable studies in conjunctival melanoma do not exist owing to the rarity of the malignancy. Conclusions: The application of combined BRAF/MEK inhibition in metastatic or unresectable conjunctival melanoma shows great potential for improving patients' prognoses. Future studies are needed to investigate the assumed benefit. (C) 2016 S. Karger AG, Basel

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Mor, Joel M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Heindl, Ludwig M. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-245771
DOI:	10.1159/000452473
Journal or Publication Title:	Ocul. Oncol. Pathol.
Volume:	3
Number:	2
Page Range:	S. 133 - 142
Date:	2017
Publisher:	KARGER
Place of Publication:	BASEL
ISSN:	2296-4657
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language TUMOR-ASSOCIATED LYMPHANGIOGENESIS; PRIMARY ACQUIRED MELANOSIS; COPY NUMBER CHANGES; CUTANEOUS MELANOMAS; MALIGNANT-MELANOMA; NRAS MUTATIONS; MEK INHIBITION; CLINICOPATHOLOGICAL FEATURES; EXTRAOCULAR-EXTENSION; IMPROVED SURVIVAL Multiple languages Ophthalmology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/24577